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Abstract: Antibiotic resistance has become a major public health problem and the antibiotics pipeline is running 
dry. Bacteriophages (phages) may offer an ‘innovative’ means of infection treatment, which can be combined or 
alternated with antibiotic therapy and may enhance our abilities to treat bacterial infections successfully. Today, in 
the Queen Astrid Military Hospital, phage therapy is increasingly considered as part of a salvage therapy for patients 
in therapeutic dead end, particularly those with multidrug resistant infections. We describe the application of a well-
defined and quality controlled phage cocktail, active against Pseudomonas aeruginosa and Staphylococcus aureus, 
on colonized burn wounds within a modest clinical trial (nine patients, 10 applications), which was approved by a 
leading Belgian Medical Ethical Committee. No adverse events, clinical abnormalities or changes in laboratory test 
results that could be related to the application of phages were observed. Unfortunately, this very prudent ‘clinical 
trial’ did not allow for an adequate evaluation of the efficacy of the phage cocktail. Nevertheless, this first ‘baby step’ 
revealed several pitfalls and lessons for future experimental phage therapy and helped overcome the psychological 
hurdles that existed to the use of viruses in the treatment of patients in our burn unit.
Keywords: Phage therapy, burn wound, infection, Pseudomonas aeruginosa, Staphylococcus aureus, antibiotic 
resistance 
Introduction
Multidrug resistance, first reported in the 
1970s, has become a major threat to the prog-
ress made in infection control worldwide. Each 
year in the EU, an estimated 25,000 patients 
die from infections with multidrug-resistant 
(MDR) bacteria [1]. Also in burn units, a large 
number of infections are virtually untreatable. 
Whereas Staphylococcus aureus remains a 
common early colonizer of burn wounds, 
Pseudomonas aeruginosa is known as the 
most common cause of life-threatening infec-
tion in burn patients [2, 3]. Both bacteria, but 
especially P. aeruginosa, are known for their 
intrinsic and acquired resistance to many anti-
biotics. Persistent multidrug-resistant P. aeru-
ginosa strains have frequently been reported to 
cause nosocomial outbreaks of infection in 
burn units [4, 5]. 
Bacteriophages (phages) are (among) the most 
abundant and ubiquitous organisms on Earth 
and are the natural controllers of bacteria. They 
are the ‘viruses’ of the bacteria and are able to 
lyse, among others, strains of S. aureus or P. 
aeruginosa, irrespective of the antibiotic sus-
ceptibility of these strains. As such, they may 
offer an independent means of infection treat-
ment, which can be combined or alternated 
with antibiotic therapy and may enhance our 
abilities to treat bacterial infections success-
fully [6]. Since the 1920s, phages have been 
used to treat all sorts of bacterial infections in 
Eastern Europe and the former USSR States, 
with the Eliava Institute in Tbilisi (Georgia) as 
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one of the key centers [7]. The advent of antibi-
otics, which exhibited a broader spectrum of 
activity and which could be produced easier in 
large quantities (i.e. in a commercially more 
profitable manner), forced phage therapy to the 
margins of Western medicine. With the world-
wide spreading of MDR bacteria, however, the 
therapeutic use of phages is going through a 
renaissance in the Western world [8]. 
The few burn wound related phage therapy 
papers in the scientific literature [9-17] suggest 
that phages could have the potential to control 
bacterial burn wound infection. 
Phages were shown to be able to rescue burned 
mice from infection caused by P. aeruginosa 
and Klebsiella pneumonia [9, 10]. In 1990, in 
Egypt, 30 patients with burn wounds were 
treated during 5-17 days with between 15 and 
45 phage-saturated dressings [11]. The clinical 
success ratio was difficult to assess because 
of the lack of validated controls, but the mere 
fact that not-endotoxin-purified phages had 
been applied massively to burn wounds, with-
out reporting adverse effects, could be indica-
tive for their intrinsic harmlessness. Soothill 
and colleagues showed that in a test popula-
tion of 14 guinea pigs with excised burn wounds 
to which 6 x 105 cfu/ml of P. aeruginosa and 
1.2 x 107 P. aeruginosa BS24 phages were 
applied simultaneously and upon which the 
excised tissue was replaced, 6 out of 7 phage 
treated grafts were not rejected, whereas all 7 
of non phage treated grafts failed [12]. Weber-
Dabrowska et al. reported the treatment of 49 
burn wounds in human patients, infected with 
P. aeruginosa, S. aureus, Escherichia coli, 
Klebsiella and/or Proteus. Forty-two patients 
fully recovered and the condition of the remain-
ing 7 patients improved markedly [13]. A 2005 
publication addressed the treatment of local 
radiation injuries in two individuals, using a 
novel biodegradable preparation capable of 
sustained release of phages and ciprofloxacin 
[14]. The same product was applied in Georgia 
on 22 patients with infected venous static 
ulcers and other poorly healing wounds, after 
standard therapy had failed [15]. Seventy per-
cent of the patients showed full recovery after a 
period ranging from 6 days to 15 months. In the 
UK, the group of Soothill reported the case of a 
27-year-old male with 50% TBSA burned and 
excised burn wounds covered with skin grafts, 
which became infected with P. aeruginosa after 
several months [16]. Grafted areas broke down 
rapidly despite appropriate antibiotic treat-
ment. Therefore, treatment with ‘purified’ phag-
es was started. Phages multiplied in the wound 
and a 43 to 1200-fold increase of phages was 
observed. Three days after phage application, 
P. aeruginosa could not be isolated from swabs 
and subsequent extensive grafting was succ- 
essful. 
There are, however, some major obstacles 
hampering the clinical application of phages in 
Western medicine [18-22]. In the EU, discus-
sions between small and medium-sized enter-
prises (SMEs) and competent authorities led to 
the classification of bacteriophages as human 
medicinal products (biologicals) regulated 
under the European Human Code for Medicines 
(Directive 2001/83/EC). A handful of compa-
nies are now struggling to take large-scale and 
uniform phage cocktails through the elaborate 
and expensive medicinal product licensing 
pathway. Funding for the development of phag-
es as medicinal products is difficult to obtain, 
since intellectual property (IP) protection for 
phages (products of nature) is very fragile. In 
addition, we feel that in hospital settings phage 
therapy would better be served by small-scale 
productions and distributions of tailor made 
phage preparations [21, 22]. Finally, but not 
less important, the reluctance to embrace 
phage therapy is also linked to the false percep-
tion of viruses, with which phages are identified 
– often without nuance –, as ‘enemies of life’ 
[23]. As a result, in the Western world, phages 
for controlling microbial contamination in food 
and the food-processing environment are read-
ily used, while no phage medicinal products are 
currently authorized for human use [24].
In 2007, we developed a well-defined phage 
cocktail, BFC-1, which was active against the P. 
aeruginosa and S. aureus strains that populat-
ed the burn wound center of the Queen Astrid 
Military Hospital.  The quality controlled pro-
duction process of BFC-1 was mainly based on 
our experience in producing cell and tissue 
autografts and allografts for human transplan-
tation (regulated under Directive 2004/23/EC 
of the European Parliament and of the Council) 
and was published in 2009 [25].
This paper gives an account of the first applica-
tion, in 2007, of BFC-1 on colonized burn 
wounds in the burn wound center of the Queen 
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Astrid Military Hospital. Since in 2007 phages 
were not yet classified as medicinal products, 
these phage applications were performed with-
in a small (9 patients, 10 single dose applica-
tions) investigator driven clinical trial (no spon-
sor) under the responsibility and supervision of 
a leading Medical Ethical Committee. The study 
was not designed according to one of the com-
mon phases (I, II or III) of the classical medici-
nal product approval process and we did not 
solicit for approval by any regulatory authority 
for future use in the general population (mar-
keting authorization). The study was notified (by 
the ethical committee) to the national compe-
tent authorities and informed consent was 
obtained from the patients. The parties involved 
in this study had no commercial interests. 
Materials and methods
Phage cocktail
The phage cocktail BFC-1, which was evaluated 
in this study, consisted of three exclusively lytic 
phages, designed for the treatment of P. aeru-
ginosa and S. aureus infections in burn wound 
patients [25]. Based on successive selection 
rounds three phages were retained from an ini-
tial pool of 82 P. aeruginosa and 8 S. aureus 
phages, specific for the P. aeruginosa and S. 
aureus strains that were the most prevalent in 
the burn wound center of the Queen Astrid 
Military Hospital. This cocktail, consisting of P. 
aeruginosa phages 14/1 (Myoviridae) and PNM 
(Podoviridae) and S. aureus phage ISP 
(Myoviridae), at a concentration of 109 plaque 
forming units (pfu)/ml of each phage, was pro-
duced and purified of endotoxin according to 
Merabishvili et al. [25]. Quality controls includ-
ed stability (shelf life), determination of pyroge-
nicity, sterility and cytotoxicity, confirmation of 
the absence of temperate phages and trans-
mission electron microscopy-based confirma-
tion of the presence of the expected virion mor-
phologic particles as well as of their specific 
interaction with the target bacteria. Phage 
genome and proteome analysis confirmed the 
lytic nature of the phages and the absence of 
toxin-coding genes.
Patients’ inclusion criteria
Nine acute burn wound patients with MDR P. 
aeruginosa and/or S. aureus burn wound colo-
nization, as determined by classical bacterial 
culture and species identification and antibiotic 
susceptibility testing using the VITEK 2 system 
(bioMérieux) of routine burn wound swabs, 
were included in this study. Pregnant women 
and patients in critical condition (APACHE II 
score > 20) were not included. Only patients 
with burn wounds that allowed for punch biopsy 
sampling were included. Patients or their legal 
representatives were provided with relevant 
and understandable information regarding the 
study and the need to give informed consent 
Figure 1. A vial of bacteriophage cocktail BFC-1.
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before they participated in the study. A no-fault 
(regardless of liability) compensation insurance 
was provided to the patients.
General trial set up
We compared the standard treatment for P. 
aeruginosa and S. aureus burn wound coloni-
zation with a phage treatment. Since an objec-
tive evaluation and classification of burn 
wounds is impossible and colonization and 
infection levels can vary significantly, we com-
pared both treatments on the same colonized 
burn wound. 
Just before the application of BFC-1, the colo-
nized burn wound was divided into two halves. 
One half received the standard treatment, the 
other half the phage treatment with BFC-1. Two 
biopsies were taken by the MD in charge of the 
patient using a 4 mm punch biopsy needle 
(Labo Stiefel); one in the centre of the zone 
where BFC-1 was to be applied, the other in the 
centre of the zone where the standard treat-
ment was to be applied. Tissue biopsies were 
preceded by local anesthesia (xylocaine 2%, 
Asta Zeneca). It was shown that infiltration with 
additive-free lidocaine 1% into a ring block 
shortly before the biopsy procedure did not 
affect the result of bacterial culture provided 
that culture was started within 2 hours [26]. 
Biopsy sites were sutured with green ethilon 
4/0 (standard treatment site) or with blue 
prolene 4/0 (BFC-1 site). The MD in charge of 
the patient applied a single-dose of approxi-
mately 1 ml of sterile and endotoxin-purified 
BFC-1 per 50 cm2 on one half of the burn 
wound, using a 5 ml syringe with a spray adapt-
er (Coster®) (Figure 1). The other half of the 
burn wound was treated with antimicrobial sub-
stances according to the standard treatment 
protocols. Patients with suspected P. aerugi-
nosa burn wound infection were administered 
amikacin (single initial dose of 25 mg/kg body 
weight) in combination with ceftazidime (single 
initial dose of 1 g) or meropenem (2 g/8 h) sys-
temically. Patients with suspected S. aureus 
burn wound infection were treated with system-
ic vancomycin (single initial dose of 1 g) or line-
zolid (2 x 600 mg/d).
A digital photograph was taken of the burn 
wound. The entire burn wound was then cov-
ered with dressings, gauze and bandages 
according to the standard treatment protocols. 
Two to five hours later, the burn wound was 
uncovered. Immediately, two biopsies were 
taken next to (within 2 cm) the previous ones. A 
digital photograph was taken of the burn 
wound. The entire burn wound was further 
treated according to standard protocols. The 
wound biopsies were immediately weighed and 
collected into separate, sterile and adequately 
labeled microtubes (Eppendorf AG) containing 
0.5 ml of sterile phosphate buffered saline 
(PBS) and transported to the laboratory for bac-
terial load determination. 
The main objective of this study was to explore 
the hurdles that early Western phage therapy 
clinical trials would inevitably face. The second-
ary objective was to document eventual 
adverse events and therapeutic effects.  
Determination of bacterial load
The biopsies were immediately homogenized, 
on ice, for 1 min at 30000 rpm, using a tissue 
tearer (Biospec Products, Inc.). Serial tenfold 
dilutions of the homogenized wound biopsy 
samples were spread, in triplicate, on blood 
agar, Manitol Salt Agar (MSA) and cetrimide 
agar plates (media were purchased from 
Becton Dickinson). Colony counts were per-
formed after overnight incubation at 37°C. The 
bacterial load, expressed as colony forming 
units (cfu) per g tissue, was calculated for each 
biopsy.
Monitoring of eventual adverse events
Patient medical files were screened for adverse 
events, clinical abnormalities and changes in 
laboratory test results that could be related to 
the application of phages. Clinical abnormali-
ties that were screened for included cardiovas-
cular, renal, and respiratory complications and 
pain. Clinical laboratory tests included the 
blood formula and standard haemostasis, bio-
chemical, pharmacological and toxicological 
parameters.
Informed consent and approval of a leading 
Medical Ethical Committee
This clinical trial was conducted with the under-
standing and the consent of the human sub-
jects. The study protocol was cleared by the 
Medical Ethical Committee of the Vrije 
Universiteit Brussel (VUB), which also notified 
the competent authorities.
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Results
Ten BFC-1 applications were performed on 9 
patients (4 males, 5 females; mean age 61 
years; age range, 27 to 88 years; mean TBSA 
burned, 30%; TBSA burned range, 6-45%). The 
surface of the burn wounds to which BFC-1 was 
administered averaged 95 cm² (range 25-150 
cm²) and on average 0.03 ml of BFC-1 (equat-
ing 107 phages) per cm² were applied in a sin-
gle dose. The second biopsies were obtained 
181 min (range 120-240 min) after BFC-1 appli-
cation. Standard treatment consisted of 
Isobetadine® gel (Meda Pharma) (n = 4) and 
Mepilex® Ag (Mölnlycke) (n = 1). Five applica-
tions occurred within the time frame of a surgi-
cal procedure, prior to which the burn wounds 
had been washed with Hibitane (5%) and fil-
tered tab water. 
The 10 burn wounds to which BFC-1 was admin-
istered were colonized or infected with MDR 
(resistance to a representative of at least 3 
classes of antibiotics) strains of P. aeruginosa 
(n = 7), S. aureus (n = 1) or both P. aeruginosa 
and S. aureus (n = 2). This distinction was 
based on the results of the most recent routine 
bacteriological screening of the burn wounds, 
associated to relevant clinical signs and bio-
logical markers. Despite the initial indications 
of colonization or infection, bacterial cultures of 
the homogenised biopsies taken before and 
after BFC-1 application showed only a very 
small bacterial load (a few colonies) in 8 of the 
10 applications. In the two remaining applica-
tions bacterial loads before BFC-1 application 
were 103 and 108 cfu per g tissue. In all cases, 
the bacterial load remained unchanged, after 
BFC-1 application as well as after standard 
treatment.
No adverse events were reported and no clini-
cal or laboratory test abnormalities related to 
the application of phages were observed.
Discussion
Hurdles 
It was far from easy to get this small pilot study 
on the rail. We had to disarm a lot of resistance. 
This reluctance towards phage therapy was 
expected and was largely due to pre- and mis-
conceptions about phage therapy. For example, 
we were asked to submit our phage cocktail to 
the National approval system for Genetically 
Modified Organisms (GMO), in which the safety 
for humans, animals and the environment is 
thoroughly assessed. Then, the experts of the 
insurance company that was asked to provide 
the no-fault compensation insurance assimi-
lated phages with viruses and consequently 
assigned our modest experiment to risk class 5 
(on a scale from 1 to 7), which resulted in a 
relatively high premium. Some editors and 
reviewers, who evaluated a former paper 
describing the quality controlled production of 
our phage cocktail, asked for conventional 
pharmaceutical tests and clinical trials, which 
take many years and cost millions of euros. 
They reckoned phages should be considered as 
classical drugs. Although phages are therapeu-
tic agents, we disagree on the fact they have to 
be considered as classical drugs. Phages are 
evolving natural controllers of bacteria. If one 
were to consider them as a stable ‘drug’, and 
apply the whole regulatory framework thereof, 
their composition and characteristics are not 
meant to vary. Unfortunately, bacteria are 
expected to escape such ‘stable’ phage prepa-
rations and the real power of the use of phages 
would be lost. The real added value of phages 
as antimicrobials relies on the possibility to 
generate certified phage preparations on faster 
time scales than those common for classical 
medicinal products. Then and only then will we 
have a ‘new’ powerful and sustainable tool in 
the fight against bacterial diseases. Hence, if 
they are to be successful, phages cannot be 
considered as classical molecules and will thus 
need a dedicated regulatory framework with 
adequate and realistic production and quality 
control requirements [20].
Pitfalls
During this study, we were confronted with 
some significant technical and logistic prob-
lems. We opted for biopsy samples to monitor 
the bacterial load of the burn wounds because 
they are still considered to be the gold standard 
by the majority of researchers [2, 27, 28]. On 
reflection, we found this technique to be very 
elaborate (e.g. necessitated local anesthesia 
and complex sample processing) and at some 
occasions we were confronted with patient 
and/or nursing aversion to biopsies. All in all, 
biopsy sampling turned out to impede the clini-
cal trial in our burn wound center. In the future, 
we will likely opt for semi-quantitative swab cul-
tures instead of quantitative biopsy cultures for 
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the monitoring of burn wound colonization, 
even if this is bound to result in less accurate 
quantification of burn wound colonization or 
infection.
The disappointing bacterial load of wound tis-
sue at the moment of BFC-1 application was 
probably due to the long period (up to 7 days) 
between initial detection of a potential candi-
date with MDR P. aeruginosa and/or S. aureus 
burn wound colonization and the actual enroll-
ment of this patient in the study. Major reasons 
for this were the delays in receiving antibio-
grams and obtaining informed consent. 
Meanwhile patients were treated with potent 
topical antimicrobials, dressings and systemic 
antibiotics. Some treatments were even applied 
minutes before the start of the trial. In the 
future, we will probably use clinical signs and 
biological markers of burn wound colonization 
or infection, instead of deferred bacteriological 
results, as inclusion criterion for this type of 
clinical trial. This would of course imply the 
inclusion of all P. aeruginosa and S. aureus 
burn wound infections, not only those with MDR 
strains. Finally, the sprayed BFC-1 cocktail had 
the tendency to run off the burn wound. The 
use of a suitable carrier, such as a gel or a 
dressing that is compatible with phage activity, 
seems more appropriate.
Notwithstanding these pitfalls, we were not 
expecting that a one-off application of 3 ml of 
BFC-1 on a small wound surface would gener-
ate conclusive proof of the efficacy of BFC-1.
Why publish (now)?
This study ran from the end of 2007 until 2008 
and we planned to publish a report in a peer-
reviewed scientific journal in the course of 
2008. However, we decided to abandon the 
idea of a widespread scientific report of this 
study because it did not go as expected. We 
would use the experience gained during this 
small pilot study to set up a larger double blind 
study. Unfortunately, we had to put our plans on 
hold because meanwhile phages were classi-
fied as medicinal products and the subsequent 
and unattainable obligation to comply with the 
classical pharmaco-economical framework. We 
had waived publication, but colleagues from 
like-minded research groups were interested in 
the fate of our study and encouraged us to pub-
lish our experiences, as they might be helpful in 
convincing their competent authorities and 
ethical committees in approving experimental 
phage applications and in designing future 
studies. In addition, the study is increasingly 
mentioned (obviously without citing a peer-
reviewed publication) in other scientific papers 
and this often without including relevant facts 
and details. Finally, we realized that this study 
had been an essential and necessary step 
towards the acceptance of phage therapy in our 
burn wound center. Since then the medical and 
nursing staff of our hospital has grown familiar 
with phages and deemed them safe for topical 
use on burn wounds. Today, phage therapy is 
increasingly part of the successful treatment of 
a handful of ‘abandoned’ patients with MDR 
infections, outside of a clinical trial and con-
form to the requirements of article 37 the 
Declaration of Helsinki (Unproven Interventions 
in Clinical Practice). Recently, the Belgian 
Ministry of Defense approved a feasibility study 
for the establishment of a dedicated phage 
therapy center in the Queen Astrid Military 
Hospital. On the first of June 2013, Phagoburn 
(www.phagoburn.eu), a project funded by the 
European Commission under the 7th Framework 
Programme for Research and Development 
was launched. It aims at evaluating phage ther-
apy for the treatment of burn wounds infected 
with Escherichia coli and P. aeruginosa. 
Conclusions
This small pilot study did identify some signifi-
cant pitfalls and hurdles associated with phage 
therapy related clinical trials and broke down 
the psychological barriers with the healthcare 
team. The local topical application of bacterio-
phage cocktail BFC-1 on 10 burn wounds in 9 
patients did not elicit any adverse events 
whatsoever.
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